Primary aldosteronism: Diagnostic and treatment strategies

Nature Clinical Practice Nephrology

Volumn 2, Issue 4, 2006, Pages 198-208

  Mattsson, Cecilia ^a   Young Jr , William F ^b,c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

Author keywords

Adrenalectomy; Hyperaldosteronism; Mineralocorticoid receptor; Potassium; Renin

Indexed keywords

ALDOSTERONE; AMILORIDE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE;

ADRENAL GLAND; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION;

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ADRENALECTOMY; ALDOSTERONE; ALGORITHMS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; FLUDROCORTISONE; HUMANS; HYPERALDOSTERONISM; HYPOKALEMIA; RECEPTORS, MINERALOCORTICOID; RENIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33646880232     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0151     Document Type: Review

References (91)

1. Hajjar I and Kotchen TA (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290: 199-206
2. Conn JW (1955) Presidental address: part I painting background; part II primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3-17
3. Conn JW and Conn ES (1961) Primary aldosteronism versus hypertensive disease with secondary aldosteronism. Recent Prog Horm Res 17: 389-414
4. Conn JW (1966) The evolution of primary aldosteronism: 1954-1967. Harvey Lect 62: 257-291
5. Andersen GS et al. (1988) The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens 2: 187-189
6. Berglund G et al. (1976) Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 2: 554-556
7. Fishman LM et al. (1968) Incidence of primary aldosteronism uncomplicated "essential" hypertension: a prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 205: 497-502
8. Streeten DH et al. (1979) Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 67: 403-413
9. Tucker RM and Labarthe DR (1977) Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 52: 549-545
10. Kaplan NM (1967) Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med 66: 1079-1090
11. Dunn PJ and Espiner EA (1976) Outpatient screening tests for primary aldosteronism. Aust NZ J Med 6: 131-135
12. Hiramatsu K et al. (1981) A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med 141: 1589-1593
13. Mulatero P et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045-1050
14. Mosso L et al. (2003) Primary aldosteronism and hypertensive disease. Hypertension 42: 161-165
15. Gordon RD et al. (1994) High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21: 315-318
16. Loh KC et al. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85: 2854-2859
17. Fardella CE et al. (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85: 1863-1867
18. Lim PO et al. (2000) High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14: 311-315
19. Schwartz GL and Turner ST (2005) Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51: 386-394
20. Hamlet SM et al. (1985) Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol 12: 249-252
21. Calhoun DA et al. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40: 892-896
22. Gallay BJ et al. (2001) Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37: 699-705
23. Pratt JH et al. (1999) Levels of mineralocorticoids in whites and blacks. Hypertension 34: 315-319
24. Rayner BL et al. (2001) Screening for primary aldosteronism - normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 91: 594-599
25. Conn JW et al. (1965) Normokalemic primary aldosteronism: a detectable cause of curable "essential" hypertension. JAMA 193: 200-206
26. Mulatero P et al. (2002) Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40: 897-902
27. Rossi E et al. (2002) High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15: 896-902
28. Brown NJ (2005) Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241
29. Brilla CG et al. (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364
30. Rocha R et al. (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-1810
31. Takeda Y et al. (2001) Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 19: 635-639
32. Kozakova M et al. (2003) Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 41: 230-236
33. Stowasser M et al. (2005) Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90: 5070-5076
34. Milliez P et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243-1248
35. Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321
36. Zannad F et al. (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102: 2700-2706
37. Fallo F et al. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91: 454-459
38. Chhokar VS et al. (2005) Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111: 871-878
39. Young WF Jr (2003) Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 144: 2208-2213
40. Blumenfeld JD et al. (1994) Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 121: 877-885
41. Mansoor GA et al. (2002) Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 15: 459-464
42. Seccia TM et al. (2005) Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 12: 149-159
43. Mulatero P et al. (2004) Genetics of primary aldosteronism. J Hypertens 22: 663-670
44. So A et al. (2005) Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 23: 1477-1484
45. Young WF Jr (2003) Primary aldosteronism - treatment options. Growth Horm IGF Res 13 (Suppl A): S102-S108
46. Montori VM et al. (2001) Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 76: 877-882
47. Kaplan NM (2004) The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22: 863-869
48. Lamarre-Cliche M et al. (2005) Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 18: 56-64
49. Hirohara D et al. (2001) Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 86: 4292-4298
50. Montori VM and Young WF Jr (2002) Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 31: 619-632
51. Tiu SC et al. (2005) The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling. J Clin Endocrinol Metab 90: 72-78
52. Weinberger MH and Fineberg NS (1993) The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153: 2125-2129
53. Unger N et al. (2004) Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol 150: 517-523
54. Ferrari P et al. (2004) Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 22: 377-381
55. Olivieri O et al. (2004) Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 89: 4221-4226
56. Stowasser M and Gordon RD (2004) Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 217: 33-39
57. Lim PO et al. (2001) Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 37: 856-861
58. Young WF Jr and Klee GG (1988) Primary aldosteronism: diagnostic evaluation. Endocrinol Metab Clin North Am 17: 367-395
59. Agharazii M et al. (2001) Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37: 1440-1443
60. Thompson GB and Young WF Jr (2003) Adrenal incidentaloma. Curr Opin Oncol 15: 84-90
61. Kloos RT et al. (1995) Incidentally discovered adrenal masses. Endocr Rev 16: 460-484
62. Young WF et al. (2004) Role for adrenal venous sampling in primary aldosteronism. Surgery 136: 1227-1235
63. Lumachi F et al. (2003) Non-invasive adrenal imaging in primary aldosteronism: sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun 24: 683-688
64. Hogan MJ et al. (1976) Location of aldosterone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med 294: 410-414
65. Nomura K et al. (1990) Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 71: 825-830
66. Choyke PL (1998) From needles to numbers: can noninvasive imaging distinguish benign and malignant adrenal lesions? World J Urol 16: 29-34
67. Young WF Jr et al. (2003) Adrenalectomy for primary aldosteronism; authors' reply. Ann Intern Med 138: 157-159
68. Litchfield WR et al. (1998) Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31: 445-450
69. Stowasser M and Gordon RD (2001) Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78: 215-229
70. Sawka AM et al. (2001) Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 135: 258-261
71. Sywak M and Pasieka JL (2002) Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg 89: 1587-1593
72. Meyer A et al. (2005) Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 29: 155-159
73. Celen O et al. (1996) Factors influencing outcome of surgery for primary aldosteronism. Arch Surg 131: 646-650
74. Lo CY et al. (1996) Primary aldosteronism: results of surgical treatment. Ann Surg 224: 125-130
75. Proye CA et al. (1998) Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 124: 1128-1133
76. Zelinka T et al. (2004) Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 18: 107-111
77. Assalia A and Gagner M (2004) Laparoscopic adrenalectomy. Br J Surg 91: 1259-1274
78. Rossi H et al. (2002) Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg 68: 253-256
79. Gonzalez R et al. (2004) Laparoscopic approach reduces likelihood of perioperative complications in patients undergoing adrenalectomy. Am Surg 70: 668-674
80. Jacobsen NE et al. (2003) Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 10: 1995-1999
81. Chavez-Rodriguez J and Pasieka JL (2005) Adrenal lesions assessed in the era of laparoscopic adrenalectomy: a modern day series. Am J Surg 189: 581-585
82. Saunders BD et al. (2004) Trends in utilization of adrenalectomy in the United States: have indications changed? World J Surg 28: 1169-1175
83. Ishidoya S et al. (2005) Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol 174: 40-43
84. Ghose RP et al. (1999) Medical management of aldosterone-producing adenomas. Ann Intern Med 131: 105-108
85. Jeunemaitre X et al. (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60: 820-825
86. Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10: 23-29
87. Weinberger MH et al. (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15: 709-716
88. Fleming T (Ed.; 2005) Red Book: Pharmacy's Fundamental Reference, 438 and 614. Montvale: Thomson PDR
89. Oberleithner H et al. (2004) Human endothelium: target for aldosterone. Hypertension 43: 952-956
90. Campbell SE et al. (1993) Myocardial fibrosis in the rat with mineralocorticoid excess: prevention of scarring by amiloride. Am J Hypertens 6: 487-495
91. Dluhy RG and Lifton RP (1999) Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 84: 4341-4344